此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

一项评估健康成人从卡博特韦长效 (CAB LA) 转换后卡博特韦超长效 (CAB ULA) 的药代动力学、安全性和耐受性的研究

2026年11月4日 更新者:ViiV Healthcare

一项 1 期单臂重复剂量研究,旨在评估健康成年志愿者从长效卡博特韦转为超长效卡博特韦的药代动力学、安全性和耐受性

This study will assess the pharmacokinetics (PK), safety, and tolerability of CAB ULA administered every 4 months (Q4M) following administration of CAB LA every 2 months (Q2M), in healthy adult volunteers.

研究概览

地位

主动,不招人

详细说明

The participants in the study will receive CAB LA in the CAB LA phase and CAB ULA in the CAB ULA phase.

研究类型

介入性

注册 (实际的)

69

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Alabama
      • Mobile、Alabama、美国、36608
        • GSK Investigational Site
    • Florida
      • Doral、Florida、美国、33172-2513
        • GSK Investigational Site
    • Illinois
      • Oak Brook、Illinois、美国、60532
        • GSK Investigational Site

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Adult participants greater than or equal to (>=) 18 years old, weighing at least 35 kg.
  • Participants who are overtly healthy as determined by medical evaluation.
  • Assigned male sex at birth or assigned female sex at birth. Participants assigned female sex at birth are eligible to participate if they are of non-childbearing potential, or if they are of childbearing potential and are not pregnant (confirmed by test), not breastfeeding, and are using a highly effective contraceptive method.
  • Capable of giving written informed consent.

Healthcare staff will be eligible for inclusion in this study if:

  • They are site employees responsible for administrative or clinical aspects of offering and administering CAB under the protocol at the site.
  • Has the required qualifications according to their role and delegated the appropriate responsibilities by site Principal investigator (PI).
  • Be able to understand and comply with protocol requirements, instructions, and restrictions.

Exclusion Criteria:

  • Presence or history of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, haematological, neurological, or psychiatric disorders capable of significantly altering drug pharmacokinetics, interfering with the participant's ability to comply with the dosing schedule and/or protocol evaluations, or compromising participant safety.
  • Current or anticipated need for chronic anti-coagulants.
  • Any malignancy within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years.
  • History of ongoing or clinically relevant seizure disorder within the previous 2 years.
  • Participants who pose a significant suicidality risk.
  • History or presence of sensitivity to any of the study medications, study procedure-related medications, their components or drugs of their class, or an allergy that contraindicates participation.
  • Participant has an implant/enhancement (including fillers) at the area of proposed injection; or tattoo or other dermatological condition overlying any area which may significantly interfere with interpretation of injection site reactions.
  • Inflammatory skin conditions that compromise the safety of injections.
  • Any acute laboratory abnormality that should preclude participation or exclusionary laboratory value.
  • Human immunodeficiency virus (HIV-1 or HIV-2) infection.
  • Reactive or positive HIV test.
  • Signs and symptoms suggestive of acute HIV infection- that is not ruled out with non-reactive results using appropriate HIV tests.
  • Presence of hepatitis B surface antigen (HBsAg) at screening or within 3 months prior to first dose of study intervention.
  • Positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study intervention.
  • Positive hepatitis C RNA test result at screening or within 3 months prior to first dose of study intervention.
  • One or more exclusionary values for a screening ECG.
  • Participants receiving any protocol-prohibited medication.
  • Use of CAB LA for PrEP within 1 year.
  • Concurrent participation in another clinical study in which an investigational product was received within 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
  • Participation in the study would result in loss of blood or blood products in excess of 500 mL within 56 days.
  • Exposure to more than 4 new chemical entities within 12 months prior to the first dosing day.
  • Positive pre-study drug/alcohol screen.
  • History of or on-going high-risk behaviours that put the participant at increased risk for HIV infection.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:其他
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:CAB Group

Participants will receive the CAB LA Q2M regimen up to Month 9 then will receive the CAB ULA Q4M regimen up to Month 23.

CAB LA injection will be administered

CAB ULA injection will be administered

研究衡量的是什么?

主要结果指标

结果测量
大体时间
CAB LA 期结束时 CAB 血浆浓度与 CAB ULA 期结束时 CAB 血浆浓度的比较
大体时间:第 23 个月与第 9 个月相比
第 23 个月与第 9 个月相比

次要结果测量

结果测量
措施说明
大体时间
CAB ULA 注射后每个评估时间点的 CAB 血浆浓度
大体时间:直至第 23 个月
直至第 23 个月
实验室异常的参与者人数
大体时间:直至第 32 个月
直至第 32 个月
实验室参数随时间变化的参与者数量
大体时间:直至第 32 个月
直至第 32 个月
Number of participants with adverse events (AEs) (including Injection Site Reactions [ISRs]) as per severity
大体时间:Up to Month 32

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. Severity is graded according to the Division of Acquired Immunodeficiency Syndrome (DAIDS) grading criteria, where Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = potentially life-threatening.

Up to Month 32
Number of participants with ISRs by grade
大体时间:Up to Month 32

Severity of ISRs is graded according to the DAIDS grading criteria, where Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = potentially life-threatening

Up to Month 32
Duration (Days) of ISRs by grade
大体时间:Up to Month 32

Severity of ISRs is graded according to the DAIDS grading criteria, where Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = potentially life-threatening.

Up to Month 32

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年1月17日

初级完成 (估计的)

2027年3月8日

研究完成 (估计的)

2027年3月8日

研究注册日期

首次提交

2025年1月15日

首先提交符合 QC 标准的

2025年1月15日

首次发布 (实际的)

2025年1月22日

研究记录更新

最后更新发布 (实际的)

2026年11月9日

上次提交的符合 QC 标准的更新

2026年11月4日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.viiv-studyregister.com/documents/About_ViiV_Patient_Level_Data_Sharing_Final_25Sep2023.pdf

IPD 共享时间框架

Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

IPD 共享访问标准

Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

IPD 共享支持信息类型

  • 研究方案
  • 树液
  • 国际碳纤维联合会
  • 企业社会责任

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅